Nature Reviews Drug Discovery contents February 2013 Volume 12 Number 2 pp 83-168

Advertisement
Tecan offers AlphaScreen® option for Infinite® F200 PRO reader Tecan has developed an AlphaScreen® module for its popular Infinite® F200 PRO multimode reader. Providing a cost-effective solution for AlphaScreen and AlphaLISA® assays, it offers excellent sensitivity for screening and research applications, further extending the flexibility of the Infinite F200 PRO. AlphaScreen and AlphaLISA are registered trademarks of PerkinElmer, Inc., USA www.tecan.com/alphascreen
TABLE OF CONTENTS
February 2013 Volume 12 Number 2		Advertisement
Impact Factor 29.008 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Also this month  Featured article: Clinical targeting of the TNF and TNFR superfamilies Michael Croft, Chris A. Benedict & Carl F. Ware	Academy of Military Medical Sciences - Celebrating 60 years of research at one of China's leading organizations for medical science. The Academy of Military Medical Sciences (AMMS) in Beijing has developed beyond its military heritage to become a world leader in medical science with a string of achievements in both military and civilian applications that have resonated around the globe. Find out more about the AMMS in Part 5 of the five-part series of this special sponsor feature on nature.com
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
PK/PD Summit Improved PK/PD Modeling & Analysis to Optimize Translation of Preclinical Data into the Clinic 19 - 21 March 2013 | Boston, MA Featuring invaluable insights and case studies from PK/PD experts at Pfizer, J&J, Eli Lilly, Merck, MedImmune, AstraZeneca, Eisai, Novartis and Amgen among others. www.pkpd-boston.com
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Nature Reprint Collection on Epigenetics This collection of articles focuses on histone methylation, its links to human disease and the development of chemical modulators of histone methylation states as leads for chromatin-targeted drug discovery. Produced exclusively with support from:
In this issue p83 | doi:10.1038/nrd3945 Full Text
Comment: Beyond magic bullets: true innovation in health care Vaibhav A. Narayan, Marco Mohwinckel, Gary Pisano, Michael Yang & Husseini K. Manji p85 | doi:10.1038/nrd3944 Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
2012 FDA drug approvals Asher Mullard p87 | doi:10.1038/nrd3946 FDA drug approval bonanza sees cancer and orphan drugs on top again. PDF
NEWS IN BRIEF Pharma's M&A 'firepower' wanes as biotech's waxes | Breakthrough drug programme debuts | SGLT2 moves p91 | doi:10.1038/nrd3947 PDF
BIOBUSINESS BRIEFS Target watch: Drugging the epigenome Samia Burridge p92 | doi:10.1038/nrd3943 PDF
PATENT WATCH Single EU patent — nearly there | Crestor survives generics challenge | Eosinophil-associated disorders Charlotte Harrison p94 | doi:10.1038/nrd3948 PDF
AN AUDIENCE WITH Mike Yeadon p96 | doi:10.1038/nrd3936 Mike Yeadon discusses the challenges of starting a company based on assets licensed from Pfizer following the closure of its research operations in Sandwich, UK. PDF
FROM THE ANALYST'S COUCH Smoking cessation drugs market Basharut A. Syed & Kritika Chaudhari p97 | doi:10.1038/nrd3914 There are an estimated 1.3 billion smokers worldwide, and nearly six million people die from tobacco-related diseases each year. This article discusses smoking cessation drugs that are in development or on the market, and provides an outlook for their commercial potential. PDF
RESEARCH HIGHLIGHTS Top Antibacterial drugs: New antibiotics on the horizon? p99 | doi:10.1038/nrd3940 PDF Neurodegenerative disease: Targeting pre-existing plaques in AD p100 | doi:10.1038/nrd3939 PDF Anticancer drugs: Assault on MALT1 p100 | doi:10.1038/nrd3942 PDF Computational chemistry: Homing in on desired drug properties p101 | doi:10.1038/nrd3938 PDF Cancer: Tuning anticancer T cells p102 | doi:10.1038/nrd3941 PDF IN BRIEF Bone disorders: A new promoter of bone regeneration | Infectious disease: A broad protozoan drug target? | Neuromuscular disorders: Reducing androgen receptor-mediated toxicity | Neurological disease: Inflammasome activation in Alzheimer's disease PDF Drug Discovery JOBS of the week Drug Discovery for Parasites University of California, San Diego Faculty of Science - Lecturer in Drug Delivery - 2 Posts University of East Anglia Postdoctoral researcher Columbia University Medical Center Postdoctoral Researcher in Organic Synthesis Uppsala University Postdoctoral Position in Mathematical Biology Program for Evolutionary Dynamics More Science jobs from Drug Discovery EVENT Resources for Computational Drug Discovery 12.09.13 Cambridge, UK More science events from
PERSPECTIVES		Top
OPINION Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective Marc Maliepaard, Charity Nofziger, Marisa Papaluca, Issam Zineh, Yoshiaki Uyama, Krishna Prasad, Christian Grimstein, Michael Pacanowski, Falk Ehmann, Silvia Dossena & Markus Paulmichl p103 | doi:10.1038/nrd3931 Pharmacogenetics is an increasingly important tool for drug development, which has been reflected in recent guidelines from regulatory agencies on the application of pharmacogenetics in studies of investigational drugs. In this article, authors from Europe, the United States and Japan overview the guidelines from the regulatory agencies in each region and discuss the common themes and differences. Abstract | Full Text | PDF
REVIEWS		Top
Targeting eosinophils in allergy, inflammation and beyond Patricia C. Fulkerson & Marc E. Rothenberg p117 | doi:10.1038/nrd3838 The accumulation of eosinophils in blood and tissue is associated with several inflammatory and infectious diseases. Here, the authors describe recent advances in the development of first-generation eosinophil-targeted therapies and highlight innovative new strategies — such as inhibiting eosinophil activation — that are aimed at targeting eosinophils. Abstract | Full Text | PDF
Advances in targeting cell surface signalling molecules for immune modulation Sheng Yao, Yuwen Zhu & Lieping Chen p130 | doi:10.1038/nrd3877 Immunomodulatory biologics targeting cell surface signalling proteins on immune cells allow immune responses to be driven in desired directions — enhancing these in infection or cancer, or dampening them in autoimmune diseases or transplantation. In this Review, Chen and colleagues discuss immunomodulatory signalling pathways that provide targets for immunomodulation, and the current state of drug development in the field. Abstract | Full Text | PDF
Clinical targeting of the TNF and TNFR superfamilies Michael Croft, Chris A. Benedict & Carl F. Ware p147 | doi:10.1038/nrd3930 The clinical success of inhibitors of tumour necrosis factor (TNF) in the treatment of autoimmune diseases has generated interest in the therapeutic potential of targeting other members of the TNF superfamily (TNFSF) of cytokines and their receptors. Here, Croft and colleagues review the current developmental status of biologics targeting these molecules in a range of disorders, highlighting key challenges and emerging therapeutic targets. Abstract | Full Text | PDF | Supplementary information
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2011 Journal Citation Report (Thomson Reuters, 2012)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.